Table 2 Factors associated with rituximab response in cohorts 1 and 2
From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Characteristic | EULAR non-responders | EULAR responders | Univariate | p value | Multivariate | p value | ||
|---|---|---|---|---|---|---|---|---|
OR (95% CI) | OR (95% CI) | |||||||
Cohort 1 (n = 111) | DAS28-CRP | 3.2–5.1 (Ref) | 12 (46.2%) | 14 (53.8%) | 4.0 (1.55–10.36) | 0.004 | 5.24 (1.85–14.85) | 0.002 |
>5.1 | 15 (17.6%) | 70 (82.4%) | ||||||
RF or anti-CCP | Negative (Ref) | 7 (41.2%) | 10 (58.8%) | 2.59 (0.88–7.67) | 0.08 | 3.48 (1.04–11.60) | 0.04 | |
Positive | 20 (21.3%) | 74 (78.7%) | ||||||
IgG > ULN (g/L) | No (Ref) | 21 (30.9%) | 47 (69.1%) | 2.76 (1.01–7.52) | 0.048 | 2.82 (0.97–8.14) | 0.056 | |
Yes | 6 (14.0%) | 37 (86.0%) | ||||||
Detectable IL-33 | No (Ref) | 23 (27.4%) | 61 (72.6%) | 2.17 (0.62–6.95) | 0.19 | – | – | |
Yes | 4 (14.8%) | 23 (85.2%) | ||||||
Cohort 2 (n = 74) | Disease activity DAS28-CRP | 3.2–5.1 (Ref) | 14 (36.8%) | 24 (63.2%) | 2.92 (0.97–8.73) | 0.056 | – | – |
>5.1 | 6 (16.7%) | 30 (83.3%) | ||||||
RF or anti-CCP | Negative (Ref) | 2 (100%) | 0 (0%) | 14.72 (0.34–629.71) | 0.16 | 32.76 (0.7–999) | 0.076 | |
Positive | 18 (25.0%) | 54 (75%) | ||||||
IgG > ULN (g/L) | No (Ref) | 15 (37.5%) | 25 (62.5%) | 2.10 (0.58–7.57) | 0.26 | – | – | |
Yes | 4 (22.2%) | 14 (77.8%) | ||||||
Detectable IL-33 | No (Ref) | 14 (35.9%) | 25 (64.1%) | 2.71 (0.91–8.10) | 0.07 | 3.73 (1.12–12.38) | 0.03 | |
Yes | 6 (17.1%) | 29 (82.9%) | ||||||